Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo

1 Jan 2023

Abstract excerpt

Background: Peptide receptor radionuclide therapy (PRRT) increases progression-free survival and quality of life of neuroendocrine tumor (NET) patients, however complete cures are rare and dose-limiting toxicity has been reported. PRRT induces DNA damage of which DNA double strand breaks (DSBs) are the most cytotoxic. DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a key player in DSB repair and its...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Research Studies
Share to Neuroblastoma Research and Treatments
Share to Neuroendocrine Tumor Research Advances

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37351169
DOI: 10.7150/thno.82963

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivoPMID 37351169Read ↗

Understanding the Radiobiological Mechanisms Induced by 177Lu-DOTATATE in Comparison to External Beam Radiation TherapySemantic proximity Read ↗

Radiosensitization of NET cells by HSP90 inhibitor ganetespib is mediated through pleiotropic stress responsesSemantic proximity Read ↗

Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARPSemantic proximity Read ↗

MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy.Semantic proximity Read ↗

Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy.Semantic proximity Read ↗

Whole genome and exome sequencing of pancreatic neuroendocrine tumour to investigate PRRT response.Semantic proximity Read ↗

Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapySemantic proximity Read ↗

Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Advanced Neuroendocrine Tumours (NETs) in a Limited Resource EnvironmentSemantic proximity Read ↗

Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cellsSemantic proximity Read ↗

Establishment of Novel Neuroendocrine Carcinoma Patient-Derived Xenograft Models for Receptor Peptide-Targeted TherapySemantic proximity Read ↗

A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing-tumor as a potential target of peptide receptor imaging and therapySemantic proximity Read ↗

Upregulation of Somatostatin Receptor Type 2 in a Receptor-Deficient <i>In Vivo</i> Pancreatic Neuroendocrine Tumor Model Improves Tumor Response to Targeted <sup>177</sup> Lu-DOTATATESemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.